

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** DAVID J. GLASS ET AL.

**Serial No.:** to be assigned                      **Group:** to be assigned

**Filing Date:** Concurrently Herewith      **Examiner:** to be assigned

**Title:** HIV-SPECIFIC FUSION PROTEINS AND THERAPEUTIC AND  
DIAGNOSTIC METHODS FOR USE

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§ 1.56 and 1.97**

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450.

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.


This Information Disclosure Statement is being filed:

- [X] (b) Within three months of the filing date of the above referenced application; within three months of the entry of an international application into the national phase; before the mailing date of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is required for the submission.

**Fees**

No fee is required for the filing of this Information Disclosure Statement.  
If any additional fee should be deemed necessary, the Commissioner is hereby authorized to charge Deposit Account Number 18-0650.

Respectfully submitted

  
\_\_\_\_\_  
Valeta Gregg  
Reg. No. 35,127  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 345-7400

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No. : REG 990A  
Serial No. : to be assigned  
Applicant: : David J. Glass al.  
Date Filed : Concurrently herewith  
For : HIV-SPECIFIC FUSION PROTEINS  
AND THERAPEUTIC AND  
DIAGNOSTIC METHODS FOR USE  
  
Examiner : Not Yet Known  
Group Art Unit : Not Yet Known

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

## U.S. PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Patent Date</u>	<u>Name</u>	<u>Class/ Subclass</u>	<u>Filing Date</u>
_____	5,897,861	Apr. 27, 1999	Fanger et al.		May 16, 1994

## FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/ Subclass</u>	<u>Translation</u> <u>Yes</u> <u>No</u>
_____	_____	_____	_____	_____	_____

OTHER DOCUMENTS

Examiner  
Initials

EXAMINER  
CONSIDERED


DATE

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:

  
Valeta Gregg  
Reg. No. 35,127  
Attorneys for Applicant  
Patent Agent for Applicant  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 345-7400